Cystic fibrosis screening

Jump to: navigation, search

Cystic fibrosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cystic fibrosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiography or Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cystic fibrosis screening On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cystic fibrosis screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cystic fibrosis screening

CDC on Cystic fibrosis screening

Cystic fibrosis screening in the news

Blogs on Cystic fibrosis screening

Directions to Hospitals Treating Cystic fibrosis

Risk calculators and risk factors for Cystic fibrosis screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2]

Overview

Newborn screening identified most of the children with cystic fibrosis before the symptoms develop. It offers this opportunity for early diagnosis and improved outcomes. Immunoreactive trypsinogen (IRT) of serum is raised in newborns with cystic fibrosis and has been used as a screening test. A raised IRT in the first week of life is a sensitive test but not specific for cystic fibrosis.

Screening

References

  1. Gonska T, Ratjen F (October 2015). "Newborn screening for cystic fibrosis". Expert Rev Respir Med. 9 (5): 619–31. doi:10.1586/17476348.2015.1085804. PMID 26366807.
  2. Hale JE, Parad RB, Dorkin HL, Gerstle R, Lapey A, O'Sullivan BP, Spencer T, Yee W, Comeau AM (October 2010). "Cystic fibrosis newborn screening: using experience to optimize the screening algorithm". J. Inherit. Metab. Dis. 33 (Suppl 2): S255–61. doi:10.1007/s10545-010-9117-3. PMID 20521170.
  3. Rock MJ, Mischler EH, Farrell PM, Bruns WT, Hassemer DJ, Laessig RH (1989). "Immunoreactive trypsinogen screening for cystic fibrosis: characterization of infants with a false-positive screening test". Pediatr. Pulmonol. 6 (1): 42–8. PMID 2704582.
  4. Paracchini V, Seia M, Raimondi S, Costantino L, Capasso P, Porcaro L, Colombo C, Coviello DA, Mariani T, Manzoni E, Sangiovanni M, Corbetta C (2012). "Cystic fibrosis newborn screening: distribution of blood immunoreactive trypsinogen concentrations in hypertrypsinemic neonates". JIMD Rep. 4: 17–23. doi:10.1007/8904_2011_55. PMC 3509858. PMID 23430892.

Linked-in.jpg